Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Ras superfamily of small GTPases consists of over 150 monomeric proteins that act as molecular switches to regulate a vast array of cellular signaling pathways [1]. These proteins cycle between an active GTP-bound state and an inactive GDP-bound state, a process tightly controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) [2]. The superfamily is categorized into five main families: Ras, which regulates cell growth and survival; Rho, which governs cytoskeletal dynamics; Rab, which manages vesicle docking and fusion; Arf, involved in vesicle formation; and Ran, which controls nucleocytoplasmic transport [1,3]. Dysregulation of these proteins, particularly through gain-of-function mutations in Ras isoforms, is a primary driver in approximately 30% of all human cancers [2]. Although long considered undruggable due to their high affinity for GTP and lack of traditional binding pockets, recent therapeutic advances have successfully targeted specific mutations like KRAS G12C using allele-specific covalent inhibitors [4]. Current research also explores the inhibition of post-translational modifications, such as farnesylation, which are required for the membrane association and functional activity of these GTPases [4]. (Sources: [1] Wennerberg K, et al. J Cell Sci. 2005; [2] Colicelli J. Sci STKE. 2004; [3] Homma Y, et al. FEBS J. 2021; [4] Canon J, et al. Nature. 2019).
Covalent inhibition of specific mutant alleles (e.g., KRAS G12C), inhibition of post-translational prenylation via farnesyltransferase or geranylgeranyltransferase inhibitors, and disruption of guanine nucleotide exchange factor (GEF) interactions.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras superfamily small GTPases (Ras superfamily).